LeMaitre acquires Xenotis for $7.7M LeMaitre Vascular acquired Xenotis on August 14. Total consideration for 100% of Xenotis' shares was $7.7M, consisting of $5.1M at the closing, $1.4M due August 13, 2015 and assumed bank debt of $1.2M. In its fiscal year ended June 30, Xenotis broke even on sales of $2.3M, or approximately $3.4M if sold through LeMaitre's sales channel. LeMaitre acquired the Xenotis building with an appraised value of $1.9M as part of this $7.7M transaction.
News For LMAT From The Last 14 Days
Check below for free stories on LMAT the last two weeks.